For research use only. Not for therapeutic Use.
HRN 00430（Cat No.:I028889）is an experimental small molecule compound being studied for its potential therapeutic applications in cancer treatment. It is designed to target specific signaling pathways involved in tumor growth and progression. The compound has shown preclinical promise in inhibiting the proliferation of various cancer cell lines, potentially by modulating key cellular mechanisms such as apoptosis and cell cycle regulation. Research is ongoing to better understand its mechanism of action, efficacy, and safety profile. HRN 00430 may offer a novel approach in cancer therapy if successful in clinical trials.
| Catalog Number | I028889 |
| Synonyms | N-azidoacetylmannosamine-tretraacylated (Ac4ManNAz); Ac4ManNAz; HRN 00430; HRN-00430; HRN00430 |
| Molecular Formula | C16H22N4O10 |
| Purity | 90% |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| IUPAC Name | (3S,4R,5S,6R)-6-(acetoxymethyl)-3-(2-azidoacetamido)tetrahydro-2H-pyran-2,4,5-triyl triacetate |
| InChI | InChI=1S/C16H22N4O10/c1-7(21)26-6-11-14(27-8(2)22)15(28-9(3)23)13(16(30-11)29-10(4)24)19-12(25)5-18-20-17/h11,13-16H,5-6H2,1-4H3,(H,19,25)/t11-,13+,14-,15-,16?/m1/s1 |
| InChIKey | HGMISDAXLUIXKM-LIADDWGISA-N |
| SMILES | O=C(CN=[N+]=[N-])N[C@H]1[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)OC1OC(C)=O |
| Reference | 1: Han SS, Lee DE, Shim HE, Lee S, Jung T, Oh JH, Lee HA, Moon SH, Jeon J, Yoon S, Kim K, Kang SW. Physiological Effects of Ac4ManNAz and Optimization of Metabolic Labeling for Cell Tracking. Theranostics. 2017 Mar 1;7(5):1164-1176. doi: 10.7150/thno.17711. eCollection 2017. PubMed PMID: 28435456; PubMed Central PMCID: PMC5399584. |
